Variable Drug Response: Genetic Evaluation

Michael PH Stumpf, University College London, London, UK
David B Goldstein, University College London, London, UK

Published online: January 2006

DOI: 10.1038/npg.els.0006001

Pharmacogenetics is the study of genetic variation in response to drugs. Although there is some evidence that drug response genotypes cluster in ethnic groups, this effect is less important than individual variation.

Keywords: pharmacogenetics; pharmacogenomics; drug evaluation; population differentiation; medical genetics; quantitative traits; association studies

 References
    book Cavalli-Sforza LL, Mennazzi P and Piazza A (1996) The History and Geography of Human Genes. Princeton, NJ: Priceton University Press.
    Daly MJ, Rioux JD, Schaffner SF, Hudson TJ and Lander ES (2001) High-resolution haplotype structure in the human genome. Nature Genetics 29: 229–232.
    He N, Yan FX, Huang SL, et al. (2002) CYP2C19 genotype and S-mephenytoin 4¢-hydroxylation phenotype in a Chinese Dai population. European Journal of Clinical Pharmacology 58: 15–18.
    Marx J (2002) Gene mutation may boost risk of heart arrhythmias. Science 297: 1252.
    Pritchard JK, Stephens M and Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155: 945–959.
    Risch N, Burchard EG, Ziv E and Tang H (2002) Categorization of humans in biomedical research: genes, race and disease. Genome Biology 3: 1–12.
    Romualdi C, Balding D, Nasidze IS, et al. (2002) Patterns of human diversity, within and among continents, inferred from biallelic DNA polymorphisms. Genome Research 12: 602–612.
    Splawski I, Timothy KW, Tateyama M, et al. (2002) Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 297: 1333–1336.
    Wilson JF, Weale ME, Smith AC, et al. (2001) Population genetic structure of variable drug response. Nature Genetics 29: 265–269.
    Xie HG, Kim RB, Wood AJ and Stein CM (2001) Molecular basis of ethnic differences in drug disposition and response. Annual Review of Pharmacology and Toxicology 41: 815–850.
 Further Reading
    book Elston RC, Olson JM and Palmer LJ (eds.) (2002) Biostatistical Genetics and Genetic Epidemiology. Chichester, UK: John Wiley.
    Goldstein DB and Chiki L (2002) Human migrations and population structure: what we know and why it matters. Annual Review of Genomics and Human Genetics 3: 129–152.
    Lewontin RC (1972) The appointment of human diversity. Evolutionary Biology 6: 381–398.
    book Licino J and Wong ML (eds.) (2002) Pharmacogenomics. Weinheim: Wiley-VCH.
    book McLeod HL and Ameyaw MM (2002) "Ethnicity and pharmacogenomics". In: Licino J and Wong ML (eds.) Pharmacogenomics, pp. 489–514. Weinheim: Wiley-VCH.
    Meyer UA and Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annual Review of Pharmacology and Toxicology 37: 269–296.
    Nebert DW (1999) Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clinical Genetics 56: 247–258.
    book Weber WW (1997) Pharmacogenetics. New York: Oxford University Press.
    Xie HG, Kim RB, Wood AJ and Stein CM (2001) Molecular basis of ethnic differences in drug disposition and response. Annual Review of Pharmacology and Toxicology 41: 815–850.
 Web Links
    ePath Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19 (CYP2C19); Locus ID: 1557. LocusLink: http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=1557
    ePath Cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6 (CYP2D6); Locus ID: 1565. LocusLink: http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=1565
    ePath Sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3) (SCN5A); Locus ID: 6331. LocusLink: http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=6331
    ePath Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19 (CYP2C19); MIM number: 124020. OMIM: http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?124020
    ePath Cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6 (CYP2D6); MIM number: 124030. OMIM: http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?124030
    ePath Sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3) (SCN5A); MIM number: 600163. OMIM: http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?600163

Related Sub-Topics:

Population Structure and Genetics | Pharmacogenetics and Pharmacogenomics | Techniques and Tools in Clinical Genetics | Linkage Analysis | Gene Mapping by Disease Association | Inter-Individual Variation and Polymorphism
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Variable Drug Response: Genetic Evaluation
 
How to Cite close
Stumpf, Michael PH, and Goldstein, David B(Jan 2006) Variable Drug Response: Genetic Evaluation. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0006001]